What Researchers Did
This review article discussed the clinical role of radionuclide therapies, specifically 131I-MIBG therapy and radioimmunotherapy, for treating neuroblastoma.
What They Found
For recurrent or progressive metastatic neuroblastoma, 131I-MIBG therapy achieved an overall objective response rate of 35% and compared favorably in invasiveness and toxicity to other treatments. When used at diagnosis for inoperable stage III and IV neuroblastoma, it was as effective as combination chemotherapy but with less toxicity. Notably, combining 131I-MIBG therapy with hyperbaric oxygen therapy in recurrent disease showed encouraging effects on survival.
What This Means for Canadian Patients
Canadian patients with neuroblastoma, particularly those with recurrent or advanced disease, might benefit from exploring radionuclide therapies like 131I-MIBG. The promising observation of combining 131I-MIBG with hyperbaric oxygen therapy offers a potential avenue for improving survival outcomes, warranting further investigation for this challenging pediatric cancer.
Canadian Relevance
Neuroblastoma is a recognized medical condition in Canada. While the study itself is not Canadian, it discusses therapies for neuroblastoma, including a mention of hyperbaric oxygen therapy, which is relevant to Canada Hyperbarics' research interests.
Study Limitations
The review notes that intensified treatments and radioimmunotherapy approaches were associated with considerable toxicity and side effects.